Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 32 of 5804
-
New pill could boost leukemia treatment for patients with specific gene changes
Disease control Recruiting nowThe current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leuke…
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted antibody plus chemotherapy enters phase 3 trial
Disease control Not yet recruitingPancreatic cancer, which stands as one of the most lethal malignancies and a leading cause of cancer-related deaths globally, poses a significant challenge to human health worldwide. However, standard chemotherapeutic regimens show limited effectiveness in advanced pancreatic can…
Phase: PHASE3 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for advanced liver cancer: radiation boosts immunotherapy in major trial
Disease control Recruiting nowThis phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant par…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could your own tumor cells stop lung cancer from returning?
Disease control Recruiting nowAfter receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Ph…
Phase: PHASE2 • Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New ALS drug trial hopes to slow disease progression
Disease control OngoingThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with …
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene therapy aims to stop sickle cell pain crises
Disease control Recruiting nowThe purpose of this study is to evaluate the Safety and Efficacy of DREAM01, a gene therapy for Sickle Cell Disease (SCD). The therapy consists of transplanting autologous CD34+ cells transduced ex vivo with a bifunctional lentiviral vector expressing βAS3m-globin and an anti-βS …
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Triple threat: radiation, chemo, and immunotherapy before surgery shows promise for oral cancer
Disease control Not yet recruitingThe objective of this study is to evaluate the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) in combination with chemotherapy and immunotherapy, prior to radical surgery, in enhancing the 2-year event-free survival rate and overall survival rate in patients d…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to curb soldier suicides with remote coaching
Disease control Recruiting nowThis study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from mili…
Phase: NA • Sponsor: Uniformed Services University of the Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Dual-Targeting CAR-T therapy aims to outperform standard care in advanced myeloma
Disease control Recruiting nowThis is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New mRNA vaccine against mpox enters key trial in africa
⭐️ VACCINE ⭐️ Recruiting nowThis is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 16, 2026 00:00 UTC
-
New combo treatment may spare head and neck cancer patients from disfiguring surgery
Disease control Recruiting nowThe NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible for curative-intent treatment, who will receive neo-a…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets genetic weakness in tough pancreatic cancer
Disease control Recruiting nowPancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic c…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a late stroke drug give patients a second chance?
Disease control Recruiting nowThis study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Part…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance tr…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New Dual-Target CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis research project includes patients with relapsed/refractory multiple myeloma (r/r MM) who have received more than three lines of treatment, including those with secondary recurrence, SCT recurrence, and refractory cases. Through this study, we aim to preliminarily determine …
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for advanced breast cancer: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.
Phase: PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo aims to stop breast cancer return after chemo
Disease control Recruiting nowThis is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadju…
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental T-Cell therapy takes on deadly brain virus
Disease control Recruiting nowThere is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in t…
Phase: PHASE2 • Sponsor: Hannover Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to control metastatic cancer in patients with limited spread
Disease control Recruiting nowThe combination of local consolidative therapy for oligometastases with systemic therapy offers the potential for clinical cure and significantly prolongs survival in a subset of patients with advanced metastatic disease. However, a considerable proportion of patients still do no…
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising combo aims to boost Cancer-Free survival in head and neck cancer
Disease control Recruiting nowThis study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with…
Phase: PHASE3 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC